+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06025747

Phase 1 Study of Abemaciclib with Radiation Therapy Before Surgery for High-Risk Adipocytic Retroperitoneal Sarcomas

Led by University of Washington · Updated on 2026-09-17

18

Participants Needed

1

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, side effects, and optimal dose of abemaciclib combined with radiation therapy before surgery in patients with high-risk adipocytic retroperitoneal sarcoma. This phase 1 trial aims to see how well abemaciclib, which may stop tumor growth by blocking key enzymes, works alongside radiation therapy to shrink tumors prior to surgery. Participants receive abemaciclib orally twice daily for 28 days, repeated for up to three cycles if there is no disease progression or unacceptable side effects. Radiation therapy is given in 28 fractions starting on day 15 of the first cycle. After completing radiation, patients may undergo surgery. Imaging scans such as CT or MRI are done during screening and while on the study. During the study, participants are monitored through imaging and other assessments. After finishing treatment, follow-up occurs 30 days later to check safety and outcomes. Researchers measure the recommended dose of abemaciclib with radiation, tumor response, surgical success, adverse events, and treatment discontinuation rates. The entire study lasts until surgery and includes monitoring for side effects up to a month after treatment ends.

CONDITIONS

Brief Title

A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas

Research Team

D

David Siu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here